



1614  
IFW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

5

|                        |              |
|------------------------|--------------|
| Application Number     | 10/533,838   |
| Filing Date            | May 4, 2005  |
| First Named Inventor   | Brown        |
| Art Unit               | 1614         |
| Examiner Name          | Unknown      |
| Attorney Docket Number | 100885-1P US |

### ENCLOSURES (Check all that apply)

|   |  |   |
|---|--|---|
| <input type="checkbox"/> Fee Transmittal Form<br><input type="checkbox"/> Fee Attached<br><input type="checkbox"/> Amendment/Reply<br><input type="checkbox"/> After Final<br><input type="checkbox"/> Affidavits/declaration(s)<br><input type="checkbox"/> Extension of Time Request<br><input type="checkbox"/> Express Abandonment Request<br><input checked="" type="checkbox"/> Information Disclosure Statement<br><br><input type="checkbox"/> Certified Copy of Priority Document(s)<br><input type="checkbox"/> Reply to Missing Parts/<br>Incomplete Application<br><input type="checkbox"/> Reply to Missing Parts<br>under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)<br><input type="checkbox"/> Licensing-related Papers<br><br><input type="checkbox"/> Petition<br><input type="checkbox"/> Petition to Convert to a<br>Provisional Application<br><input type="checkbox"/> Power of Attorney, Revocation<br>Change of Correspondence Address<br><input type="checkbox"/> Terminal Disclaimer<br><input type="checkbox"/> Request for Refund<br><input type="checkbox"/> CD, Number of CD(s) _____<br><input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance Communication to TC<br><br><input type="checkbox"/> Appeal Communication to Board<br>of Appeals and Interferences<br><br><input type="checkbox"/> Appeal Communication to TC<br>(Appeal Notice, Brief, Reply Brief)<br><br><input type="checkbox"/> Proprietary Information<br><br><input type="checkbox"/> Status Letter<br><input type="checkbox"/> Other Enclosure(s) (please identify<br>below): |
| <input type="checkbox"/> Remarks  |  |   |

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

|              |                 |          |        |
|--------------|-----------------|----------|--------|
| Firm Name    |                 |          |        |
| Signature    |                 |          |        |
| Printed name | Jianzhong Shen  |          |        |
| Date         | January 2, 2006 | Reg. No. | 48,076 |


### CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

|                       |            |      |                 |
|-----------------------|------------|------|-----------------|
| Signature             |            |      |                 |
| Typed or printed name | Liz Ashton | Date | January 3, 2006 |

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Appl. No.: 10/533,838

Applicant: Brown *et al.*

National Phase Fld (371): May 4, 2005

Docket No.: 100885-1P US

Customer No.: 22466

Confirmation No.: 6088

PCT Appl. No.: PCT/SE2003/001705

PCT Filed: November 5, 2003

TC/A.U.: 1614

Examiner: Unknown

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Applicants submit herewith a list of patents and publications for which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. §§ 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.


Applicants also wish to make the Examiner aware of co-pending applications:

10/477851, a PCT national phase filed on May 16, 2002;  
10/477854, a PCT national phase filed on May 16, 2002;  
10/477641, a PCT national phase filed on May 16, 2002;  
10/477821, a PCT national phase filed on May 16, 2002;  
10/491263, a PCT national phase filed on October 2, 2002;  
10/240114, a PCT national phase filed on March 30, 2001;  
10/240038, a PCT national phase filed on March 30, 2001;  
10/222990, filed on August 19, 2002;  
10/541522, a PCT national phase filed on January 13, 2004;  
10/541656, a PCT national phase filed on January 13, 2004; and  
10/541664, a PCT national phase filed on January 13, 2004.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

This Information Disclosure Statement is being filed before the mailing date of a first office action on the merits and therefore, pursuant to 37 C.F.R. § 1.97(b), no fee is required pursuant to 37 C.F.R. § 1.17(p).


Respectfully submitted,



---

Name: Jianzhong Shen  
Dated: January 2, 2006  
Reg. No. 48,076  
Phone No. 302-886-8854  
Global Intellectual Property, Patents,  
AstraZeneca,  
1800 Concord Pike,  
Wilmington, DE-19850-5437

Enclosures: Form PTO/SB/08A (1 pg)  
Form PTO/SB/08B (1 pg)  
References (12)



PTO/SB/08A (07-05)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

### Complete if Known

|                        |              |
|------------------------|--------------|
| Application Number     | 10/533,838   |
| Filing Date            | May 4, 2005  |
| First Named Inventor   | Brown        |
| Art Unit               | 1614         |
| Examiner Name          | Unknown      |
| Attorney Docket Number | 100885-1P US |

Sheet 1 of 2

### U. S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Document Number                          | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines, Where<br>Relevant Passages or Relevant<br>Figures Appear |
|--------------------|-----------------------|--|--------------------------------|--|---|
|                    |                       | Number-Kind Code <sup>2</sup> (if known) |                                |  |   |
|                    |                       | US- 2,898,339                            | 08-04-1959                     | Wheeler et al.                                     |   |
|                    |                       | US- 4,581,171                            | 04-08-1986                     | Kennis et al.                                      |   |
|                    |                       | US- 4,816,586                            | 03-28-1989                     | Portoghese   |   |
|                    |                       | US- 4,939,137                            | 07-03-1990                     | Russell et al.                                     |   |
|                    |                       | US- 5,140,029                            | 08-18-1992                     | Kennis et al.                                      |   |
|                    |                       | US- 5,574,159                            | 11-12-1996                     | Chang et al.                                       |   |
|                    |                       | US- 5,683,998                            | 11-04-1997                     | Shibayama et al.                                   |   |
|                    |                       | US- 6,187,792                            | 02-13-2001                     | Delorme et al.                                     |   |
|                    |                       | US- 6,455,545                            | 09-24-2002                     | Delorme et al.                                     |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |
|                    |                       | US-                                      |                                |  |   |

### FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. <sup>1</sup> | Foreign Patent Document   | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines,<br>Where Relevant Passages<br>Or Relevant Figures Appear | T <sup>6</sup> |
|--------------------|-----------------------|---|--------------------------------|--|---|----------------|
|                    |                       | Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known) |                                |  |   |                |
|                    |                       | WO 93/15062   | 08-05-1993                     | The Wellcome Foundation                            |   |                |
|                    |                       | WO 97/23466   | 07-03-1997                     | Astra Aktiebolag                                   |   |                |
|                    |                       | WO 98/28275   | 07-02-1998                     | Astra Pharma Inc.                                  |   |                |
|                    |                       | WO 99/33806   | 07-08-1999                     | Ortho-McNeil Pharmaceutical                        |   |                |
|                    |                       | WO 01/74804   | 10-11-2001                     | AstraZeneca AB                                     |   |                |
|                    |                       | WO 01/74806   | 10-11-2001                     | AstraZeneca AB                                     |   |                |

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |      |                                     |             |
|--|------|-------------------------------------|-------------|
| Substitute for form 1449/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(Use as many sheets as necessary)</i> |      | <b>Complete if Known</b>            |             |
|  |      | Application Number                  | 10/533,838  |
|  |      | Filing Date                         | May 4, 2005 |
|  |      | First Named Inventor                | Brown       |
|  |      | Art Unit                            | 1614        |
|  |      | Examiner Name                       | Unknown     |
| Sheet 2  | of 2 | Attorney Docket Number 100885-1P US |             |

| NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>2</sup> |
|                                 |                       | BARBER, A. et al., "Antinociceptive effects of the 5-HT <sub>2</sub> Antagonist Ritanserin in Rats: Evidence... in the Spinal Cord," Neuroscience Letters, 1989, Vol. 99, pgs 234-238   |                |
|                                 |                       | BILSKY, E. et al., "SNC 80, A Selective, Nonpeptidic and Systematically Active Opioid Delta Agonist," J. Pharmacology Experimental Ther., 1995, Vol. 273, pgs. 359-366  |                |
|                                 |                       | GREENE T., "Protective Groups in Organic Synthesis," Wiley & Sons, 1982, pgs. 218, 220, 232, 233, 251   |                |
|                                 |                       | TAKEMORI, A.E. et al., "Selective Naltrexone-Derived Opioid Receptor Antagonists," Annu. Rev. Pharmacol. Toxicol., 1992, Vol. 32, pgs. 239-269  |                |
|                                 |                       | WEI, Z. et al., "N,N-Diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide A Novel... and its Analogues," J. Med. Chem., 2000, Vol. 43, pgs. 3895-3905   |                |
|                                 |                       | ZHANG, X. et al., "Probes for Narcotic Receptor Mediated Phenomena. 26. 1-3 Synthesis... Opioid Receptor Ligands, J. Med. Chem., 1999, Vol. 42, pgs. 5455-5463  |                |
|                                 |                       |   |                |
|                                 |                       |   |                |
|                                 |                       |   |                |
|                                 |                       |   |                |

|                    |  |                 |  |
|--------------------|--|-----------------|--|
| Examiner Signature |  | Date Considered |  |
|--------------------|--|-----------------|--|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.